“…HRT has been shown to have an effective role
in the prevention and treatment of osteoporosis.
Bisphosphonates are considered as first-line options…”.1

Umbrella
What may the Hormone Therapy and Osteoporosis Umbrella include?

Depending on the Source (DotS) this Umbrella may include:

  • Hormone Replacement Therapy (HRT)
  • Hormone Therapy (HT)
  • Menopausal Hormone Therapy (MHT)
  • Osteoporosis
  • Postmenopause Osteoporosis
  • Thin Bones

Bone Loss Prevention

Is hormone therapy (HT) approved for prevention of bone loss?

On page 775 in The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points, published July 2022 and “endorsed by more than 20 well-respected international organizations”, the North American Menopause Society (NAMS) note:

  • “Hormone therapy is FDA approved for prevention of bone loss, but not for treatment of osteoporosis. (Level I)”.2

What is FDA?

FDA can be an abbreviation for the (United States) Food and Drug Administration.

What is Level I?

In this context “Level I: Based on good and consistent scientific evidence”.

Early Menopause

What is one of the highlights about early menopause included in the 2022 Hormone Therapy Position Statement of the North American Menopause Society?

On page one in The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement, published 07 July 2022, one of the highlights is:

  • “Women with primary ovarian insufficiency and premature or early menopause have higher risks of bone loss, heart disease, and cognitive or affective disorders associated with estrogen deficiency. It is recommended that hormone therapy can be used until at least the mean age of menopause unless there is a contraindication to its use”.3

Early Menopause and Breast Cancer Risk

What is one of the recommendations included in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause?

On page two in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause, first published 10 June 2022, one of the recommendations is:

  • “Women with POI and early menopause (40–45 years old) should be advised that HRT is unlikely to increase risk of breast cancer in younger menopausal women under the age of 50”.4

Postmenopausal Bone Loss

Does HT prevent bone loss in healthy postmenopausal women?

On page 775 in The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points the NAMS include:

  • “Hormone therapy prevents bone loss in healthy postmenopausal women, with dose-related effects on bone density. (Level I)”.5

Postmenopausal Fracture Risk

Does HT reduce fracture risk in healthy postmenopausal women?

On page 775 in The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points the NAMS include:

  • “Hormone therapy reduces fracture risk in healthy postmenopausal women. (Level I)”.6

Postmenopausal Osteoporosis

Can HT be used in the prevention of osteoporosis?

On page two in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause, first published 10 June 2022, one of the recommendations is:

Hormone Therapy and Osteoporosis

  • “Bisphosphonates are considered as first-line options for most patients with postmenopausal osteoporosis due to their broad spectrum of anti-fracture efficacy”.7

Bisphosphonates

What are bisphosphonates?

DotS the definition of bisphosphonates may vary. In Bisphosphonates: What Are Biphosphenates? Drugs.com elaborate on:

“Bisphosphonates are a group of medicines that slow down or prevent bone loss, strengthening bones. Bisphosphonates inhibit osteoclasts which are responsible for breaking down and reabsorbing minerals such as calcium from bone (the process is known as bone resorption). Bisphosphonates allow osteoblasts (bone building cells) to work more effectively, improving bone mass”.8

Health Care Provider

What if I choose to use HT?

If you choose to use HT it may be in your best interest to also choose to talk to your health care provider about this.

On page two in the Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause, first published 10 June 2022, one of the recommendations is:

  • “The decision whether to take HRT, the dose and duration of its use should be made on an individualised basis after discussing the benefits and risks with each patient. This should be considered in the context of the overall benefits obtained from using HRT including symptom control and improving quality of life as well as considering the bone and cardiovascular benefits associated with HRT use”.9

Health Topics A-Z

Where may I find Health Topics related to Hormone Therapy and Osteoporosis?

In Health Topics A-Z you may find:

Links

Where may I find Links related to Hormone Therapy and Osteoporosis?

Your Country may have Links similar to:

Sources

Where may I find the Sources quoted?

You may find the Sources quoted at:

Sources

  1. Hamoda et al. Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published 10 June 2022:2. https://journals.sagepub.com/doi/full/10.1177/20533691221104879 Accessed: 24 August 2022
  2. The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points. July 2022: 775. North American Menopause Society https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf Accessed: 24 August 2022
  3. The North American Menopause Society Releases Its 2022 Hormone Therapy Position Statement. 07 July 2022:1. North American Menopause Society https://www.menopause.org/docs/default-source/press-release/ht-position-statement-release.pdf Accessed: 24 August 2022
  4. Hamoda et al. Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published 10 June 2022:2. https://journals.sagepub.com/doi/full/10.1177/20533691221104879 Accessed: 24 August 2022
  5. The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points. July 2022: 775. North American Menopause Society https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf Accessed: 24 August 2022
  6. The 2022 Hormone Therapy Position Statement of The North American Menopause Society: Osteoporosis – Key Points. July 2022: 775. North American Menopause Society https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf Accessed: 24 August 2022
  7. Hamoda et al. Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published 10 June 2022:2. https://journals.sagepub.com/doi/full/10.1177/20533691221104879 Accessed: 24 August 2022
  8. Bisphosphonates: What Are Bisphosphonates? Drugs.com https://www.drugs.com/drug-class/bisphosphonates.html Accessed: 24 August 2022
  9. Hamoda et al. Joint Position Statement By the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on Best Practice Recommendations for the Care of Women Experiencing the Menopause. First Published 10 June 2022:2. https://journals.sagepub.com/doi/full/10.1177/20533691221104879 Accessed: 24 August 2022
Topic Last Updated: 24 August 2022 – Topic Last Reviewed: 24 August 2022

Print Friendly, PDF & Email